BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12433691)

  • 1. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
    Klein C; Nguyen D; Liu CH; Mizoguchi A; Bhan AK; Miki H; Takenawa T; Rosen FS; Alt FW; Mulligan RC; Snapper SB
    Blood; 2003 Mar; 101(6):2159-66. PubMed ID: 12433691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells.
    Strom TS; Turner SJ; Andreansky S; Liu H; Doherty PC; Srivastava DK; Cunningham JM; Nienhuis AW
    Blood; 2003 Nov; 102(9):3108-16. PubMed ID: 12855574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
    Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
    Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction.
    Wada T; Jagadeesh GJ; Nelson DL; Candotti F
    Hum Gene Ther; 2002 Jun; 13(9):1039-46. PubMed ID: 12067437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
    Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
    Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
    Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
    Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression.
    Yamaguchi K; Ariga T; Yamada M; Nelson DL; Kobayashi R; Kobayashi C; Noguchi Y; Ito Y; Katamura K; Nagatoshi Y; Kondo S; Katoh H; Sakiyama Y
    Blood; 2002 Aug; 100(4):1208-14. PubMed ID: 12149199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation.
    Snapper SB; Rosen FS; Mizoguchi E; Cohen P; Khan W; Liu CH; Hagemann TL; Kwan SP; Ferrini R; Davidson L; Bhan AK; Alt FW
    Immunity; 1998 Jul; 9(1):81-91. PubMed ID: 9697838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
    Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
    Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
    Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
    Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Boztug K; Dewey RA; Klein C
    Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes.
    Zhang J; Shehabeldin A; da Cruz LA; Butler J; Somani AK; McGavin M; Kozieradzki I; dos Santos AO; Nagy A; Grinstein S; Penninger JM; Siminovitch KA
    J Exp Med; 1999 Nov; 190(9):1329-42. PubMed ID: 10544204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
    Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
    J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
    Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
    Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells.
    Maillard MH; Cotta-de-Almeida V; Takeshima F; Nguyen DD; Michetti P; Nagler C; Bhan AK; Snapper SB
    J Exp Med; 2007 Feb; 204(2):381-91. PubMed ID: 17296786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.
    Braun CJ; Boztug K; Paruzynski A; Witzel M; Schwarzer A; Rothe M; Modlich U; Beier R; Göhring G; Steinemann D; Fronza R; Ball CR; Haemmerle R; Naundorf S; Kühlcke K; Rose M; Fraser C; Mathias L; Ferrari R; Abboud MR; Al-Herz W; Kondratenko I; Maródi L; Glimm H; Schlegelberger B; Schambach A; Albert MH; Schmidt M; von Kalle C; Klein C
    Sci Transl Med; 2014 Mar; 6(227):227ra33. PubMed ID: 24622513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein.
    Strom TS; Gabbard W; Kelly PF; Cunningham JM; Nienhuis AW
    Gene Ther; 2003 May; 10(9):803-9. PubMed ID: 12704420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the Wiskott-Aldrich syndrome protein N-terminal domain in transgenic mice inhibits T cell proliferative responses via TCR signaling without affecting cytoskeletal rearrangements.
    Sato M; Tsuji NM; Gotoh H; Yamashita K; Hashimoto K; Tadotsu N; Yamanaka H; Sekikawa K; Hashimoto Y
    J Immunol; 2001 Oct; 167(8):4701-9. PubMed ID: 11591801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
    Dewey RA; Avedillo Díez I; Ballmaier M; Filipovich A; Greil J; Güngör T; Happel C; Maschan A; Noyan F; Pannicke U; Schwarz K; Snapper S; Welte K; Klein C
    Exp Hematol; 2006 Sep; 34(9):1161-9. PubMed ID: 16939809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.
    Uchiyama T; Adriani M; Jagadeesh GJ; Paine A; Candotti F
    Mol Ther; 2012 Jun; 20(6):1270-9. PubMed ID: 22215016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.